Areas where scientific evidence is lacking or incomplete.
Large-scale, long-term studies for romosozumab and denosumab are lacking. The safety profile of PTH analogs beyond 2 years remains undetermined. The relevance of rodent osteosarcoma findings to human risk is unknown.
Implications: Patients and clinicians cannot confidently assess long-term risks of newer bone-density therapies, limiting informed decision-making for extended treatment courses.
Extracellular vesicles and exosomes for bone density remain in animal models only, with no Phase I-III trials as of late 2025. Nanomedicines have no clinical trials. Gut-derived peptides (GIP, GLP-1, GLP-2) show promise in rodent models but results have not been fully translated to humans.
Implications: Promising preclinical therapies are unavailable to patients, and there is no timeline for when these approaches might reach clinical use.
The majority of bone density research has been conducted in postmenopausal women. Data on younger at-risk individuals is scarce. Study populations lack ethnic and racial heterogeneity, limiting generalizability.
Implications: Treatment recommendations may not apply to men, younger adults, or non-white populations, leaving these groups without evidence-based guidance for bone density management.
Evidence for sequential therapy approaches in bone density treatment is rated as low quality. No standardized regimen exists for collagen peptides regarding dose, type, or timing.
Implications: Clinicians lack reliable guidance on how to sequence therapies for maximum benefit, and patients using collagen supplements have no evidence-based dosing protocols to follow.
Medication adherence remains a significant barrier due to treatment burden, side effects, and lack of patient trust. Real-world BMD monitoring strategies are insufficient, and better response biomarkers are needed to track treatment effectiveness.
Implications: Even effective therapies may fail in practice if patients discontinue treatment, and clinicians lack reliable tools to monitor whether a chosen therapy is working for a given patient.
The molecular mechanisms underlying how diabetes affects bone quality and fracture risk are incompletely understood, described in the literature as an area of incomplete understanding.
Implications: Diabetic patients face elevated fracture risk but cannot receive targeted bone-protective interventions because the underlying pathways are not yet clear enough to guide therapy.
The role of myokines and osteokines in mediating bone-muscle cross-talk and their contribution to indirect fracture prevention requires further exploration.
Implications: Potential combined exercise and pharmacological strategies targeting both bone and muscle remain speculative, and patients miss out on interventions that could address fracture risk through musculoskeletal integration.
Expert disagreements and competing evidence.
PTH analogs carry an osteosarcoma black box warning with a strict 2-year lifetime treatment limit.
Based on rodent carcinogenicity studies that showed dose- and duration-dependent osteosarcoma in rats. Abaloparatide labeling still carries the boxed warning. Many clinical references and formularies continue to cite the 2-year lifetime limit for all agents in this class.
FDA removed the boxed warning from Teriparatide in Nov 2020 based on retrospective human data, and updated guidance indicates treatment beyond 2 years may be considered for high-risk patients. Abaloparatide retains the warning.
FDA's Nov 2020 label revision for Teriparatide removed the boxed warning, citing a 15-year post-marketing surveillance study and retrospective epidemiological data showing no increased osteosarcoma incidence in humans. Endocrine Society and AACE guidelines now note that extending anabolic therapy beyond 2 years may be considered when fracture risk remains very high.
Verdict Note
The warning status now differs by agent: FDA removed it for Teriparatide but retained it for Abaloparatide. The 2-year limit remains the default recommendation, but updated clinical guidance acknowledges extended use may be appropriate in high-fracture-risk patients, making the blanket 2-year rule an oversimplification.
Anabolic agents (Teriparatide, Abaloparatide, Romosozumab) should be first-line therapy for patients at very high fracture risk.
AACE 2020 and Endocrine Society 2020 guidelines stratify patients by fracture risk and recommend initiating anabolic therapy first in very-high-risk patients (e.g., recent vertebral fracture, T-score below -3.0, high FRAX score), followed by antiresorptive consolidation.
PTH analogs are second-line agents requiring documented bisphosphonate failure or intolerance before approval.
Step-therapy protocols from major insurers (Independence Blue Cross, Eastern Oregon CCO, and similar plans) require documented failure of or intolerance to oral bisphosphonates before authorizing PTH analogs or Romosozumab, regardless of clinical risk stratification.
Verdict Note
Clinical guidelines and insurance coverage diverge. Evidence-based guidelines from AACE and the Endocrine Society support anabolic-first sequencing for very high risk patients, but payer step-therapy policies (IBX, EOCCO, and others) classify these agents as second-line, creating a gap between guideline recommendations and real-world access.
Romosozumab is a monoclonal antibody that inhibits sclerostin, producing dual effects: stimulating bone formation and reducing resorption.
FDA-approved labeling, the ARCH trial (Saag et al., NEJM 2017), and the FRAME trial (Cosman et al., NEJM 2016) all describe Romosozumab as binding and inhibiting sclerostin, thereby increasing Wnt signaling, stimulating osteoblast-mediated bone formation, and concurrently reducing bone resorption.
Romosozumab targets the RANKL pathway.
A single bibliometric analysis misattributed Romosozumab's mechanism to the RANKL pathway. No primary pharmacological or clinical source supports this classification. This is a misidentification likely confusing Romosozumab with Denosumab.
Verdict Note
Romosozumab (Evenity) is definitively a sclerostin inhibitor. The RANKL attribution appears in one bibliometric analysis and is a factual error. RANKL inhibition is the mechanism of Denosumab (Prolia/Xgeva). All primary pharmacological references, the FDA label, and the ARCH/FRAME trial publications confirm sclerostin as Romosozumab's target.
Long-term effectiveness of calcium and vitamin D supplementation for osteoporosis is limited and not ideal as a standalone intervention.
The WHI calcium/vitamin D trial and subsequent meta-analyses showed modest effects on BMD and inconsistent fracture risk reduction, with some analyses finding no significant hip fracture benefit in intention-to-treat populations. As monotherapy for established osteoporosis, Ca+VitD is considered inadequate.
Calcium and vitamin D are foundational co-factors essential to osteoporosis treatment, and pharmacological agents only achieve significant BMD gains when paired with adequate Ca+VitD.
All major osteoporosis drug trials (HORIZON, FREEDOM, VERO, ARCH, FRAME) provided Ca+VitD to all participants. Clinical guidelines universally recommend ensuring adequate calcium (1000-1200 mg/day) and vitamin D (800-2000 IU/day) as baseline co-therapy. Vitamin D deficiency is associated with blunted response to bisphosphonates and anabolic agents.
Verdict Note
Both claims are partially correct and address different questions. Ca+VitD alone produces modest BMD improvements and inconsistent fracture reduction, making them insufficient as standalone therapy for established osteoporosis. However, they are necessary co-interventions: clinical trials of bisphosphonates, PTH analogs, and other agents all administered Ca+VitD as background therapy, and deficiency demonstrably blunts pharmacological response. The claims are complementary, not contradictory.
MK-677 is anabolic to bone, increasing the formation marker P1NP by approximately 23%.
One analysis highlighted the P1NP increase (~23%) to frame MK-677 as having anabolic bone effects, without reporting concurrent resorption marker changes.
MK-677 stimulates overall bone turnover, increasing both formation markers (P1NP) and resorption markers (CTx +26%), rather than producing a net anabolic-only effect.
Primary clinical research (e.g., Murphy et al.) measured both P1NP and CTx in MK-677-treated subjects and found concurrent increases in both markers — P1NP rising alongside CTx (+26%). This is consistent with GH/IGF-1 physiology, which stimulates osteoblast and osteoclast activity in a coupled fashion, increasing total turnover rather than shifting the balance purely toward formation.
Verdict Note
Primary research data shows MK-677 increases both bone formation and resorption markers, consistent with a general increase in bone turnover mediated by GH/IGF-1 stimulation rather than a selective anabolic effect. Characterizing MK-677 as purely anabolic to bone oversimplifies its mechanism and may overstate its therapeutic value for osteoporosis.
Anabolic therapy should be given first, before antiresorptive agents, because this sequence produces greater BMD gains. Prior antiresorptive use blunts subsequent PTH analog response.
The DATA-Switch extension study showed that patients receiving Teriparatide first followed by Denosumab achieved greater total hip and spine BMD gains than the reverse sequence. Studies have shown that prior alendronate or Denosumab use attenuates the P1NP response and early BMD gains from subsequently administered Teriparatide.
Anabolic therapy after antiresorptive treatment is sometimes clinically preferred and can still be effective despite a blunted initial response.
Many patients are already on bisphosphonates or Denosumab at the time of fracture or treatment escalation. Discontinuing Denosumab without alternative therapy risks rebound vertebral fractures, so transitioning to Teriparatide (with bisphosphonate bridge) is sometimes required. While the initial BMD response is blunted, anabolic agents still improve bone microarchitecture and reduce fracture risk in these patients over the treatment course.
Verdict Note
Evidence supports that treatment-naive patients achieve larger BMD gains when starting with an anabolic agent (DATA-Switch, VERO extensions). Prior bisphosphonate or Denosumab use does attenuate the early BMD response to Teriparatide. However, in clinical practice many patients present already on antiresorptives, and switching to an anabolic still provides benefit — just with a slower onset. Additionally, transitioning off Denosumab without an alternative risks rebound bone loss and vertebral fractures, making anabolic sequencing after Denosumab a clinically necessary, if suboptimal, pathway. The optimal sequence depends on patient history and clinical context.